HIV Infections Clinical Trial
Official title:
Assessing the Feasibility, Acceptability and Effects Of HIV Birth Testing In Maternity Settings In Zimbabwe
NCT number | NCT04206241 |
Other study ID # | EG0219 |
Secondary ID | |
Status | Completed |
Phase | |
First received | |
Last updated | |
Start date | January 1, 2018 |
Est. completion date | December 31, 2019 |
Verified date | August 2021 |
Source | Elizabeth Glaser Pediatric AIDS Foundation |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Observational |
This study aims to assess the feasibility and, acceptability and effects of implementing HIV testing at birth testing using point-of-care (POC) HIV nucleic acid testing (NAT) in maternity settings.
Status | Completed |
Enrollment | 278833 |
Est. completion date | December 31, 2019 |
Est. primary completion date | November 1, 2018 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | N/A to 48 Hours |
Eligibility | Inclusion Criteria: HIV-exposed infants (HEI) - All HEI who access maternity/post-natal services within 48 hours of life - Tested for HIV at birth using the POC NAT platform - Caregiver provides informed consent for participation Caregivers - Mother/caregiver of an HEI who was offered POC EID at birth - Able to provide informed consent to participate in the study Health workers - All health workers working in maternity services in the study sites - Provides informed consent to be interviewed Key informants (laboratory managers and program leads/focal persons) - Health managers working in the field of pediatric HIV services or PMTCT - Provides informed consent to be interviewed Exclusion Criteria: HIV-exposed infants (HEI) - HEI tested for HIV using conventional EID at project sites - HEI whose caregivers refuse birth testing - HEI where the clinician deems there is a contra-indication for sample collection for birth testing (e.g. severe hemophilia) Caregivers - Caregivers of HEI who cannot legally provide consent to participate in the study Health workers - Healthcare workers who do not make use of EID or results of EID Key informants - Key informants who cannot legally provide consent to participate in the study |
Country | Name | City | State |
---|---|---|---|
Zimbabwe | Beitbridge District Hospital | Beitbridge | |
Zimbabwe | Bindura Provincial Hospital | Bindura | |
Zimbabwe | Chegutu District Hospital | Chegutu | |
Zimbabwe | Norton Hospital | Chegutu | |
Zimbabwe | Chiredzi District Hospital | Chiredzi | |
Zimbabwe | Gweru Provincial Hospital | Gweru | |
Zimbabwe | Victoria Falls District Hospital | Hwange | |
Zimbabwe | Kadoma District Hospital | Kadoma | |
Zimbabwe | Kwekwe General Hospital | Kwekwe | |
Zimbabwe | Masvingo Provincial Hospital | Masvingo |
Lead Sponsor | Collaborator |
---|---|
Elizabeth Glaser Pediatric AIDS Foundation | UNITAID |
Zimbabwe,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Proportion of eligible HEI who present to pilot facilities who receive POC EID testing at birth | Number of eligible HEI who received POC EID divided by the total number of eligible HEI | 18 months | |
Secondary | Proportion of tested HEI whose caregivers receive results of the POC EID birth testing | Number of HEI whose caregivers received results of the POC EID birth testing, divided by the number of HEI who received POC EID birth testing | 18 months | |
Secondary | Average number of days between sample collection of HEI and results received by caregiver | Date HEI sample collected minus date results received | 18 months | |
Secondary | Proportion of HEI tested at birth who are HIV positive | Number of HEI tested at birth who are HIV positive divided by the number of HEI tested at birth | 18 months | |
Secondary | Proportion of HIV-infected infants tested at birth who are started on ART within 2 weeks of the birth test | Number of HIV-infected infants tested at birth who are started on ART within 2 weeks of the birth test, divided by the number of HIV-infected infants tested at birth | 18 months | |
Secondary | Average number of days between sample collection of HEI and initiation on ART for infants testing HIV-positive | Date of sample collection of HEI minus date of date of ART initiation on ART for infants testing HIV-positive | 18 months | |
Secondary | Proportion of infants testing HIV negative at birth and who return for testing at 6-8 weeks | Number of infants testing HIV-negative at birth who return for testing at 6-8 weeks, divided by the number of infants who tested HIV-negative at birth | 18 months | |
Secondary | Proportion of infants who test HIV-positive at 6-8 weeks of those who test negative at birth | Number of infants who test HIV-positive at 6-8 weeks divided by those who tested HIV-negative at birth | 18 months | |
Secondary | The retention in care of positively-identified infants on birth testing for the first 3 and/or 6 months of life | Number of infants who tested HIV-positive at birth in care at 3 and/or 6 months of life, divided by the number who tested HIV-positive at birth | 18 months | |
Secondary | Proportion of HEI tested at birth who meet criteria for high risk of vertical transmission | Number of HEI tested at birth who meet the criteria for high risk of vertical transmission divided by the number who meet the criteria for high risk of vertical transmission | 18 months | |
Secondary | Proportion of high-risk infants according to the risk screening tool who test HIV-positive at birth | Number of high-risk infants according to the risk screening tool who test HIV-positive at birth, divided by the number of high-risk infants according to the risk screening tool | 18 months | |
Secondary | Proportion of low-risk infants according to the risk screening tool who test HIV-positive at birth | Number of low-risk infants according to the risk screening tool who test HIV-positive at birth, divided by the number of low-risk infants according the risk screening tool | 18 months |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05454514 -
Automated Medication Platform With Video Observation and Facial Recognition to Improve Adherence to Antiretroviral Therapy in Patients With HIV/AIDS
|
N/A | |
Completed |
NCT03760458 -
The Pharmacokinetics, Safety, and Tolerability of Abacavir/Dolutegravir/Lamivudine Dispersible and Immediate Release Tablets in HIV-1-Infected Children Less Than 12 Years of Age
|
Phase 1/Phase 2 | |
Completed |
NCT03141918 -
Effect of Supplementation of Bioactive Compounds on the Energy Metabolism of People Living With HIV / AIDS
|
N/A | |
Completed |
NCT03067285 -
A Phase IV, Open-label, Randomised, Pilot Clinical Trial Designed to Evaluate the Potential Neurotoxicity of Dolutegravir/Lamivudine/Abacavir in Neurosymptomatic HIV Patients and Its Reversibility After Switching to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide. DREAM Study
|
Phase 4 | |
Recruiting |
NCT04579146 -
Coronary Artery Disease (CAD) in Patients HIV-infected
|
||
Completed |
NCT06212531 -
Papuan Indigenous Model of Male Circumcision
|
N/A | |
Active, not recruiting |
NCT03256422 -
Antiretroviral Treatment Taken 4 Days Per Week Versus Continuous Therapy 7/7 Days Per Week in HIV-1 Infected Patients
|
Phase 3 | |
Completed |
NCT03256435 -
Retention in PrEP Care for African American MSM in Mississippi
|
N/A | |
Completed |
NCT00517803 -
Micronutrient Supplemented Probiotic Yogurt for HIV/AIDS and Other Immunodeficiencies
|
N/A | |
Active, not recruiting |
NCT03572335 -
Systems Biology of Diffusion Impairment in Human Immunodeficiency Virus (HIV)
|
||
Completed |
NCT04165200 -
Fecal Microbiota Transplantation as a Therapeutic Strategy for Patients Infected With HIV
|
N/A | |
Recruiting |
NCT03854630 -
Hepatitis B Virus Vaccination in HIV-positive Patients and Individuals at High Risk for HIV Infection
|
Phase 4 | |
Terminated |
NCT03275571 -
HIV, Computerized Depression Therapy & Cognition
|
N/A | |
Completed |
NCT02234882 -
Study on Pharmacokinetics
|
Phase 1 | |
Completed |
NCT01618305 -
Evaluating the Response to Two Antiretroviral Medication Regimens in HIV-Infected Pregnant Women, Who Begin Antiretroviral Therapy Between 20 and 36 Weeks of Pregnancy, for the Prevention of Mother-to-Child Transmission
|
Phase 4 | |
Recruiting |
NCT05043129 -
Safety and Immune Response of COVID-19 Vaccination in Patients With HIV Infection
|
||
Not yet recruiting |
NCT05536466 -
The Influence of Having Bariatric Surgery on the Pharmacokinetics, Safety and Efficacy of the Novel Non-nucleoside Reverse Transcriptase Inhibitor Doravirine
|
N/A | |
Recruiting |
NCT04985760 -
Evaluation of Trimer 4571 Therapeutic Vaccination in Adults Living With HIV on Suppressive Antiretroviral Therapy
|
Phase 1 | |
Completed |
NCT05916989 -
Stimulant Use and Methylation in HIV
|
||
Terminated |
NCT02116660 -
Evaluation of Renal Function, Efficacy, and Safety When Switching From Tenofovir/Emtricitabine Plus a Protease Inhibitor/Ritonavir, to a Combination of Raltegravir (MK-0518) Plus Nevirapine Plus Lamivudine in HIV-1 Participants With Suppressed Viremia and Impaired Renal Function (MK-0518-284)
|
Phase 2 |